/

Regencell Bioscience Holdings Limited

RGC US

RGC USRegencell Bioscience Holdings Limited

United States Composite

6.00

USD

+0.73

(+13.85%)

-0.45EPS Dil.

-13.30P/E

78.08MMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Held by Insiders

88.76%

Held by Institutions

0.13%

Short % of Float

0.03%

YTD Yield

-76.24%

Capital Structure

FRC

•

in mil. unless spec.

Jun'22

Dec'23

Jun'23

ST Debt

premium

LT Borrowings

premium

LT Finance Leases

premium

Preferred Equity and Hybrid Capital

premium

Shares Outstanding

premium

Market Capitalization

premium

Working Capital

FRC

•

in mil. unless spec.

Jun'22

Dec'23

Jun'23

Total Current Assets

premium

Cash, Cash Equivalents & STI

premium

Accounts Receivable, Net

premium

Inventories

premium

Total Current Liabilities

premium

Payables & Accruals

premium

ST Debt

premium

Deferred Revenue

premium

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

premium

Net Income, GAAP

premium

Free Cash Flow

premium

Total Cash Common Dividend

premium

Total Equity

premium

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

premium

- -

premium

2022

premium

- -

premium

2023

premium

- -

premium

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

premium

- -

premium

2022

premium

- -

premium

2023

premium

- -

premium

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

premium

- -

premium

2022

premium

- -

premium

2023

premium

- -

premium

Company Description

CEO: Mr. Yat-Gai Au
Full Time Employees: 12
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: Chinachem Leighton Plaza Causeway Bay Hong Kong
CIK: 0001829667
Website: www.regencellbioscience.com
Business: Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.